# US 2025/0144097 A1 · Compositions and methods for preventing and treating neurodegenerative diseases with diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144097 A1
- Document ID: US20250144097A1
- Status: Published application
- Kind: A1
- Application number: 19/003,429
- Filed: 2024-12-27
- Published: 2025-05-08
- Earliest claimed: 2022-06-29
- Assignees: Aribio Co., Ltd.
- Applicants: Aribio Co., Ltd.
- Inventors: Jai Jun Choung
- Web page: https://patentgrep.com/patent/US20250144097A1

## CPC

- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a composition for preventing or treating a neurodegenerative disease containing a phosphodiesterase-5 (PDE-5) inhibitor and an anti-diabetic therapeutic including sodium-glucose cotransporter 2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (PPD-4) inhibitor and a method using thereof, wherein the PDE5 inhibitor is selected from among mirodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, pharmaceutically acceptable salts, solvates, hydrates, and a mixture thereof; and the SGLT2 inhibitor is selected from among canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, tofogliflozin, remogliflozin etabonate, sergliflozin etabonate, pharmaceutically acceptable salts, solvates, hydrates and a mixture thereof; and the neurodegenerative disease is selected from the group among dementia, Parkinson's disease (PD), Dementia with Lewy body (DLB), Alzheimer's disease (AD), Huntington's disease (HD), Multiple sclerosis (MS), Vascular Dementia (VaD), Amyotrophic Lateral Sclerosis (ALS), frontotemporal dementia, or a mixed etiologies thereof.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A pharmaceutical composition comprising:
at least one phosphodiesterase 5 inhibitor; and
at least one anti-diabetic therapeutic, or pharmaceutically acceptable salts, solvates, hydrates of said phosphodiesterase 5 inhibitor and said acetylcholinesterase inhibitor.

### Claim 21 (depends on 20)

The pharmaceutical composition of claim 20, wherein the phosphodiesterase 5 inhibitor comprises mirodenafil, sildenafil, vardenafil, tadalafil, udenafil, dasantafil, avanafil, pharmaceutically acceptable salts, solvates, hydrates, derivatives and mixtures thereof.

### Claim 22 (depends on 20)

The pharmaceutical composition of claim 20, wherein the anti-diabetic therapeutic is an agent that (1) increases the amount of insulin secreted by the pancreas, (2) increases the sensitivity of target organs to insulin, (3) decreases the rate at which glucose is absorbed from the gastrointestinal tract, or (4) increases the loss of glucose through urination, or a mixture thereof.

### Claim 23 (depends on 20)

The pharmaceutical composition of claim 20, wherein the anti-diabetic therapeutic comprises insulin or its derivatives, Glucagon-like peptide-1 (GLP-1) or its derivatives, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or its derivatives, a dipeptidyl peptidase-4 (DPP-4) inhibitor or its derivatives, or a mixture thereof.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, wherein the SGLT2 inhibitor comprises canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, ipragliflozin, luseogliflozin, tofogliflozin, remogliflozin etabonate, or sergliflozin etabonate, and mixtures thereof.

### Claim 25 (depends on 23)

The pharmaceutical composition of claim 23, wherein the DPP-4 inhibitor comprises Sitagliptin™, Vildagliptin™, Saxagliptin™, Linagliptin™ Gemigliptin™, Anagliptin™, Teneligliptin™, Alogliptin™, Trelagliptin™ Omarigliptin™, Evogliptin™, Gosogliptin™, Dutogliptin™, or Berberine™ and mixtures thereof.

### Claim 26 (depends on 20)

The pharmaceutical composition of claim 20,
wherein
the phosphodiesterase 5 inhibitor comprises mirodenafil, and
the anti-diabetic therapeutic comprises N,N-dimethylbiguanide, a DPP-4 inhibitor, or a SGLT2 inhibitor.

### Claim 27 (depends on 20)

A method for preventing or treating neuroinflammation comprising:
administering an effective amount of the pharmaceutical composition of claim 20.

### Claim 28 (depends on 20)

A method for preventing and/or inhibiting formation and/or accumulation of beta-amyloid comprising:
administering an effective amount of the pharmaceutical composition of claim 20.

### Claim 29 (depends on 20)

A method for preventing or treating a neurodegenerative disease comprising:
administering an effective amount of the pharmaceutical composition of claim 20.

### Claim 30 (depends on 29)

The method of claim 29, wherein the neurodegenerative disease is dementia, Parkinson's disease (PD), Dementia with Lewy body (DLB), Alzheimer's disease (AD), Huntington's disease (HD), Multiple sclerosis (MS), Vascular Dementia (VaD), Amyotrophic Lateral Sclerosis (ALS), or frontotemporal dementia, or mixed etiologies thereof.

### Claim 31 (depends on 20)

A method for inhibiting Aβ Oligomer/Fibril formation by reducing Aβ aggregation comprising:
administering an effective amount of the pharmaceutical composition of claim 20.

### Claim 32 (depends on 20)

A method for inhibiting β-Amyloidogenic processing by reducing BACE-1 comprising:
administering an effective amount of the pharmaceutical composition of claim 20.

### Claim 33 (depends on 20)

A method for reducing extracellular Aβ monomers, oligomers & Aβ Fibril/Plaque by increasing cerebral blood flow comprising:
administering an effective amount of the pharmaceutical composition of claim 20.

### Claim 34 (depends on 20)

A method for suppressing neuronal cell death, promoting neurogenesis, synaptogenesis and/or angiogenesis by activating NO/cGMP/PKG/CREB Pathway comprising:
administering an effective amount of the pharmaceutical composition of claim 20.

### Claim 35 (depends on 20)

A method for restoring synaptic plasticity by activating Wint Signaling by inhibiting DKK-1 comprising:
administering an effective amount of the pharmaceutical composition of claim 20.

### Claim 36 (depends on 20)

A method for inhibiting production of APP and/or reducing Aβ accumulation by suppressing positive feedback loop for Aβ production comprising:
administering an effective amount of the pharmaceutical composition of claim 20.

### Claim 37 (depends on 20)

A method for inhibiting formation of Aβ Fibril/plaque by removing intracellular toxic and soluble Aβ oligomers by activating autophagy comprising:
administering an effective amount of the pharmaceutical composition of claim 20.

### Claim 38

A pharmaceutical composition comprising:
mirodenafil and empagliflozin, or pharmaceutically acceptable salts, solvates, hydrates.
and derivatives thereof.

### Claim 39 (depends on 38)

A method for preventing or treating neuroinflammation comprising:
administering an effective amount of the pharmaceutical composition of claim 38.

### Claim 40 (depends on 39)

A method for preventing and/or inhibiting formation of and/or accumulation of beta-amyloid comprising:
administering an effective amount of the pharmaceutical composition of claim 39.

### Claim 41 (depends on 39)

A method for preventing or treating a neurodegenerative disease comprising:
administering an effective amount of the pharmaceutical composition of claim 39.

### Claim 42 (depends on 41)

The method of claim 41, wherein the neurodegenerative disease is dementia, Parkinson's disease (PD), Dementia with Lewy body (DLB), Alzheimer's disease (AD), Huntington's disease (HD), Multiple sclerosis (MS), Vascular Dementia (VaD), Amyotrophic Lateral Sclerosis (ALS), or frontotemporal dementia, or mixed etiologies thereof.

### Claim 43 (depends on 39)

A method for inhibiting Aβ Oligomer/Fibril formation by reducing of Aβ aggregation comprising:
administering an effective amount of the pharmaceutical composition of claim 39.

### Claim 44 (depends on 39)

A method for inhibiting β-Amyloidogenic processing by reducing BACE-1 comprising:
administering an effective amount of the pharmaceutical composition of claim 39.

### Claim 45 (depends on 39)

A method for reducing extracellular Aβ monomers, oligomers & Aβ Fibril/Plaque by increasing the cerebral blood flow comprising:
administering an effective amount of the pharmaceutical composition of claim 39.

### Claim 46 (depends on 39)

A method for suppressing neuronal cell death, promoting neurogenesis, synaptogenesis and/or angiogenesis by activating NO/cGMP/PKG/CREB Pathway comprising:
administering an effective amount of the pharmaceutical composition of claim 39.

### Claim 47 (depends on 39)

A method for restoring synaptic plasticity by activating Wint Signaling by inhibiting DKK-1 comprising:
administering an effective amount of the pharmaceutical composition of claim 39.

### Claim 48 (depends on 39)

A method for inhibiting production of APP and/or reducing Aβ accumulation by suppressing positive feedback loop for Aβ production comprising:
administering an effective amount of the pharmaceutical composition of claim 39.

### Claim 49 (depends on 39)

A method for inhibiting formation of Aβ Fibril/plaque by removing intracellular toxic and soluble Aβ oligomers by activating autophagy comprising:
administering an effective amount of the pharmaceutical composition of claim 39.
